The medication is used to support the management of Essential Hypertension (high blood pressure). The medicine is indicated as substitution therapy for adult patients whose blood pressure is already adequately controlled using the three individual components taken separately. This fixed-dose combination plays a role in managing conditions characterized by increased physiological stress.

---

Treating Difficult-to-Control High Pressure

Dafiro HCT is primarily relevant in clinical settings where patients experience high blood pressure that remains inadequately controlled despite optimized dual-drug regimens. This approach is commonly used to help with symptoms that create noticeable physiological strain caused by chronic high pressure, in scenarios where additional management of discomfort is required. It is applied across domains where additional symptomatic support is needed.

---

Patient Benefit and Consistency

The primary therapeutic benefit of this combination is achieving a reduction in systemic blood pressure, which may assist with maintaining functional stability of vital organs. For patients at high cardiovascular risk, maintaining targeted blood pressure levels is commonly used to help with the reduction of long-term risk of serious cardiovascular events such as stroke and myocardial infarction. The single-pill regimen provides a supportive practical benefit by simplifying the patient's medication schedule.

“Combining three necessary medications into a single tablet may contribute to improved day-to-day comfort and supports easier consistency for long-term vascular health maintenance.”

---

Quick Fact

Quick Fact: Relief for Uncontrolled Hypertension	Description
Main Use Scenario	Applied in clinical settings that involve acute or unstable symptom patterns.
Primary Patient Benefit	Supports general well-being during symptomatic phases.

Dafiro HCT (amlodipine/valsartan/hydrochlorothiazide) is for adults whose blood pressure is already controlled by the individual components taken separately. Official regulatory documents strictly define populations who should and should not use this medicine.

Classification	Populations and Conditions
Contraindicated	Use is prohibited in patients with known hypersensitivity to the drug's components, sulfonamide derivatives, or dihydropyridine derivatives. The drug is also prohibited during the second and third trimesters of pregnancy, in cases of severe liver impairment, severe renal impairment (GFR < 30 mL/min/1.73 m^2), anuria, and in patients with refractory electrolyte imbalances (e.g., low potassium or sodium) or severe hypotension/shock.
	It is contraindicated for patients with diabetes or moderate/severe renal impairment (GFR < 60 mL/min/1.73 m^2) who are taking aliskiren-containing products.
Not Recommended	Use is generally not recommended for children and adolescents (under 18 years old) due to lack of established data, for nursing mothers, and for patients with Primary Hyperaldosteronism.
Requires Caution	Special consideration is required for elderly patients and those with heart failure, renal artery stenosis, or volume/salt depletion. Any volume or electrolyte imbalance must be corrected prior to initiating treatment.

This eligibility profile is based on the combined risks of the three active ingredients, establishing clear boundaries for its safe and proper use in the adult population.

The official regulatory profile for Dafiro HCT focuses on interaction patterns classified across three main categories: formal prohibitions, exposure modification, and pharmacodynamic reinforcement.

Contraindicated and Restricted Combinations

The use of Aliskiren is formally contraindicated in patients with diabetes mellitus or those with moderate-to-severe renal impairment, a restriction related to the increased risks of hyperkalemia and decreased renal function associated with dual blockade of the Renin-Angiotensin System (RAS). Due to the potential for excessive blood pressure lowering effects, dual blockade of the RAS using other Angiotensin Receptor Blockers or ACE Inhibitors is generally not recommended.

Exposure Modification

Exposure-altering interactions are documented, notably a 77% increase in exposure to Simvastatin when co-administered with the Amlodipine component. This finding necessitates a regulatory restriction that limits the Simvastatin dose to 20 mg daily. The absorption of the Hydrochlorothiazide component may be reduced by products such as Cholestyramine and Colestipol. Separately, the Valsartan component, a substrate of OATP hepatic uptake transporters, is expected to have increased systemic exposure when co-administered with OATP inhibitors.

Pharmacodynamic Reinforcement

Pharmacodynamic interactions include the risk of Lithium toxicity, as the combination of diuretics and ARBs reduces Lithium’s renal clearance. The co-administration of Potassium-Sparing Diuretics or potassium supplements is not recommended due to the potential for significant hyperkalemia. Furthermore, consumption of alcohol or co-administration with narcotics is documented to potentiate the risk of orthostatic hypotension.

Ontology: How Dafiro HCT Works

Modulating Hormonal Signals and Vascular Tone

The medication's action is defined by two primary vaso-modulating components. Valsartan functions as a selective antagonist, binding to the Angiotensin II Type 1 ( AT1) Receptor to block the pro-constrictive and aldosterone-releasing effects of Angiotensin II. Concurrently, Amlodipine acts as an inhibitor of Voltage-Dependent L-Type Calcium Channels in vascular smooth muscle, restricting the influx of calcium ions and promoting muscle relaxation. These distinct mechanisms converge to directly regulate vascular resistance and arterial tone.

Adjusting Fluid and Electrolyte Homeostasis

The third component, hydrochlorothiazide, contributes to systemic modulation by inhibiting the Sodium-Chloride Co-transporter ( Na^+/ Cl^- co-transporter) in the renal distal convoluted tubule. This interference with electrolyte reabsorption initiates a cascade resulting in increased water excretion (diuresis). This physiological process leads to a decrease in the circulating blood volume and the overall fluid load within the cardiovascular system.

Multi-Layered Mechanistic Synergy

The combination exhibits synergy by influencing vascular tone and fluid volume through multiple, distinct pathways. The RAAS blockade helps manage the potential physiological feedback loop—an increase in Angiotensin II—that can be stimulated by the volume depletion caused by the diuretic component.

How to Use Dafiro HCT

This section describes the standard administration protocol for adults with essential hypertension using Dafiro HCT (amlodipine/valsartan/hydrochlorothiazide).

---

Official Administration Guidelines

Instruction	Detail
Route of Administration	The medication is for oral use only.
Dosage Schedule	The regimen is once daily (one tablet per day).
Strength Selection	The initial dose is typically determined by the stable doses of the individual components (amlodipine, valsartan, and hydrochlorothiazide) that the patient was taking separately prior to switching to this combination pill.
Maximum Dose	The maximum recommended daily dosage is the 10 mg/320 mg/25 mg strength.

---

Procedural and Timing Instructions

To ensure consistent use, the tablet should be taken at the same time each day, preferably in the morning. Dafiro HCT may be taken with or without food. The film-coated tablet must be swallowed whole with some water and should not be crushed or chewed.

If a dose is missed, it is recommended to skip the missed dose and take the next dose at the usual scheduled time. A double dose should not be taken to make up for a missed tablet.

Dosage adjustments, if required, should typically be implemented at intervals of at least two weeks to allow for the full therapeutic effect of the current dose to stabilize.

---

Specific Population Constraints

Usage is not recommended for pediatric patients (under 18 years of age) due to insufficient data. Specific constraints apply to use in patients with impaired kidney function: it is not suitable for patients with severe renal impairment (glomerular filtration rate < 30 mL/min) due to the hydrochlorothiazide component.

Research Evidence / Overview of Studies for Dafiro HCT

Evidence for Use in Inadequately Controlled Essential Hypertension

This section will summarize the evidence from controlled clinical trials that studied the fixed-dose triple combination in adult patients whose high blood pressure was not reaching target goals with a dual-drug regimen.

Research examined the fixed-dose triple combination in adult patients whose essential hypertension was marked by systemic or functional imbalance and remained elevated despite prior two-drug therapy. To understand the combination's characteristics, studies employed controlled clinical trials where participants were observed over defined time intervals and compared the fixed triple combination against dual-drug combinations of the same active ingredients. These trials primarily monitored physiological strain by measuring patterns in the change in mean sitting systolic and diastolic blood pressure (BP). Subgroup analyses were also conducted, and research explored how the combination was evaluated in specific populations, including elderly patients and those with comorbidities like diabetes or obesity.

The findings from these controlled studies reported measurements showing patterns in blood pressure change across the fixed-dose triple combination and dual combinations. Studies also reported patterns where a specific percentage of participants met a predefined BP goal during the observed study period. These findings describe group patterns observed in the studies.

---

Evidence for Use as Substitution Therapy

The available research that supports using this medicine as a substitution therapy for adult patients already adequately controlled on the three individual components will be reviewed here.

For patients whose blood pressure is already adequately controlled by taking the three components (Amlodipine, Valsartan, and Hydrochlorothiazide) separately, research was examined for the use of the single, fixed-dose tablet. These studies monitored physiological strain by comparing the fixed-dose combination to the free combination of the three separate pills. Outcomes examined included systemic measures of drug exposure (to establish pharmaceutical equivalence) and measurements related to blood pressure control.

Bioequivalence research described a pattern of comparable delivery of the active ingredients into the body as the three separate pills. Controlled trials described that participants showed similar measurements related to blood pressure control when switched from the three separate pills to the single fixed-dose combination. This evidence contributes to understanding the characteristics of the fixed-dose product. The research primarily evaluated use as a substitution and did not explore initiation of treatment in patients who were not yet controlled.

Common questions about Dafiro HCT (FAQ)

Q: Will taking Dafiro HCT affect cholesterol or other lab test results?

According to official regulatory information, the hydrochlorothiazide component may cause changes in certain lab values, specifically a rise in cholesterol and triglycerides. For some patients, the regulatory documents specify the need for periodic monitoring of serum electrolytes (such as potassium and sodium), creatinine, and uric acid to track these changes.

Q: What are the signs of a potentially serious side effect from Dafiro HCT?

Official product information describes several potentially serious adverse reactions. Signs of Angioedema, which is rapid swelling, may include swelling of the face, lips, tongue, or throat, or trouble swallowing. Other risks include Acute Angle-Closure Glaucoma, which can present as sudden vision loss or eye pain.

Q: Can I take Dafiro HCT if I am already using supplements for my heart or blood pressure?

The regulatory label cautions against certain product combinations. Regulatory documents state that co-administration with potassium supplements or potassium-sparing diuretics (a type of water pill) is generally not recommended due to the risk of hyperkalaemia, or significantly high potassium levels.

Q: Are there any specific foods or diet restrictions to follow while taking Dafiro HCT?

Official administration guidelines state that Dafiro HCT may be taken with or without food. The regulatory documents do not specify any required diet or general food restrictions for administration.

Q: Is Dafiro HCT safe for long-term use?

The medicine is indicated for the long-term management of essential high blood pressure. Official evidence indicates that the reduction in blood pressure associated with this medication may lower the risk of nonfatal and fatal cardiovascular events, including strokes and myocardial infarctions.

Q: Can Dafiro HCT cause sun sensitivity or a stronger reaction to sun exposure?

The regulatory safety profile indicates that the hydrochlorothiazide component can make the skin more sensitive to sunlight, a condition known as photosensitivity. Official regulatory information specifies that patients may need to protect their skin from the sun due to this effect.

Q: Is it normal to have a dry mouth while on Dafiro HCT?

According to regulatory data on reported side effects, dry mouth has been noted in patients taking this medication. It is typically classified as an uncommon or rare event.

Q: Can Dafiro HCT affect sleep patterns?

Official safety reports indicate that some patients experience an effect on sleep patterns. Sleeplessness or trouble sleeping (insomnia) is listed as an uncommon or rare adverse reaction associated with the drug.

Q: Are there specific routine lab tests required when starting or continuing Dafiro HCT?

Official documents describe the need for specific routine monitoring for certain patients. Periodic monitoring of serum electrolytes (like potassium), creatinine, and uric acid is specified in the regulatory guidance, particularly for individuals with pre-existing kidney issues.

Q: Does official research show that Dafiro HCT helps prevent stroke or heart attack?

Official research indicates that the therapeutic effect of reducing high blood pressure may be associated with a reduced risk of fatal and nonfatal cardiovascular events. This includes a potential reduction in the risk of strokes and myocardial infarctions (heart attacks).

Q: Can Dafiro HCT cause muscle cramping or spasms in the legs?

Muscle spasms are reported in the official safety profile as a common adverse event. This means they occurred in 2% or more of patients in clinical trials.

Q: Can Dafiro HCT affect a person's heart rate?

The official safety profile notes that the medication can cause hypotension (low blood pressure). Less common side effects reported include palpitations (pounding heartbeats) and cardiac arrhythmias (irregular heart rhythm).

Q: What are the common reasons patients are advised to stop taking Dafiro HCT?

Regulatory documents specify that the medication should be discontinued immediately upon detection of pregnancy due to the potential risk of fetal harm. Discontinuation is also specified if severe and refractory hypokalaemia (low potassium) develops or if certain other severe adverse reactions occur.

Q: Is Dafiro HCT the same as the generic version?

The fixed-dose combination of amlodipine, valsartan, and hydrochlorothiazide is available in a generic version. This generic version contains the same active ingredients in the same amounts as the brand-name product.

Q: Is there a concern about weight gain associated with taking Dafiro HCT?

Based on regulatory safety data, decreased weight is reported as a rare side effect. Weight gain is not listed among the commonly reported or serious adverse events in the official safety profile.

Q: How soon after starting Dafiro HCT should blood pressure changes be monitored?

The official administration instructions state that the full blood pressure lowering effect is generally achieved within two weeks following a dose change. This two-week interval is used to guide the timing for making any potential dosage adjustments.

How to Store and Dispose of Dafiro HCT

Official regulatory documentation sets specific requirements for the storage and final disposal of Dafiro HCT (amlodipine/valsartan/hydrochlorothiazide) tablets to maintain product stability and safety.

---

Storage Requirements

Dafiro HCT must be stored at a temperature below 30°C (le 30 C). The medicine should be protected from excessive heat and moisture, and the tablets must not be frozen. A mandatory safety instruction in the official labeling is to keep the product out of the sight and reach of children.

---

Disposal Instructions

Disposal of any unused or expired Dafiro HCT must be performed in accordance with local requirements. The regulatory instructions explicitly state that the medicine must not be disposed of via wastewater (e.g., flushing) or general household waste to prevent environmental contamination.